A new stroke therapeutic based on collaborative research between the TNRR Laboratory and Aruna Bio will soon enter clinical trials. The U.S. Food and Drug Administration cleared the new drug, known as AB126, to enter a Phase 1b/2a clinical trial, which is expected to begin in the first half of 2024 . This first stage of the clinical trial will test the safety and efficacy of the Ab126 in ischemic stroke patients. Read more about this exciting news at news.uga.edu and read more about the studies that helped contribute to this advancement by clicking on the links below.
